Forging ahead with its new three-year business plan, Chugai Pharmaceutical enjoyed rosy earnings in the first half of 2019, bolstered by the outperformance of the Hemlibra (emicizumab) hemophilia drug and its I/O star Tecentriq (atezolizumab). But with a biosimilar onslaught…
HOME > TOP STORIES
TOP STORIES
-
ORGANIZATION Experts Talk over Biosimilar Challenges, Chide Unstable Supplies and Indication Gaps
July 19, 2019
-
BUSINESS IPO Pending, StemRIM Looks to File World’s 1st Regeneration-Inducing Med Next Year: CEO
July 18, 2019
-
BUSINESS Astellas Hitches Frequency’s Regenerative Hearing Loss Therapy Outside US
July 18, 2019
-
ORGANIZATION Towards 2020 Reform, JPMA Wants Its Three-Pronged Proposal to Resonate with Public
July 17, 2019
-
BUSINESS Takeda Gears Up for Clinical Testing of 1st iPS-Derived CAR-T, Eyes Trial Launch in 2021
July 17, 2019
-
TRENDS Japan SGLT2 Market Hits 70 Billion Yen as Combo Drugs Gain Ground
July 16, 2019
-
BUSINESS Simone Thomsen Tapped as Lilly Japan Chief; Patrik Jonsson to Take Big Job at HQ
July 12, 2019
-
ACADEMIA Drugs to Replace Nucleic Acid Analogs Being Developed for Hepatitis B, with Focus on Elimination of HBs Antigens
July 12, 2019
-
ACADEMIA NCC Pitches Creation of New Panel to Address Info Gaps for Cancer Drugs, but Regional Hospitals Wary
July 11, 2019
-
BUSINESS Life Science Institute Begins Muse Cell Trial for Spinal Injury; President Confident of Profitability
July 10, 2019
-
BUSINESS Daiichi Sankyo Espha Set to Push Drug Adherence for Cancer AGs, Boost Added Value for Generics
July 9, 2019
-
BUSINESS Maviret, Lyrica Sell Big; Avastin Presumed No. 1 in FY2018 Drug Ranking: Tally
July 8, 2019
-
COMMENTARY Drug Pricing Debate for 2020 Reform Going into High Gear; Industry Leery of Post-Election Surprises
July 5, 2019
-
TRENDS Japan Drug Makers’ Workforce Down 1.3% in FY2018 amid Spate of Voluntary Redundancies
July 4, 2019
-
TRENDS Drug Makers Now Required to Boost Transparency in Exec Pay; Astellas Ups Bonus, Stock Option Ratio to 70%
July 3, 2019
-
BUSINESS CheckMate-227 Lung Cancer Data Will Make or Break Opdivo’s Fate: Analyst
July 2, 2019
-
BUSINESS Takeda’s Medical Unit Revving Up “Patient First Program” as It Looks beyond the Pill
July 1, 2019
-
BUSINESS Takeda Shareholders Block Old Guard Group’s Claw-Back Pitch
June 28, 2019
-
REGULATORY Chuikyo Raises No Objection to Earlier Price Cuts for LLPs, Payers Want Stricter Rule
June 27, 2019
-
REGULATORY Drug Pricing Organization Pitches Earlier Price Cuts for LLPs If AGs Launched, PMP Tweaks and More
June 26, 2019
ページ
Generic drug makers are making greater efforts to disclose more information on their products after years of repeated requests from doctors and medical institutions, which want to better ascertain their quality and stability of their supplies.Ohara Pharmaceutical has been disclosing…
Riding on the back of an improved regulatory environment in China, major Japanese drug makers are moving to expand their businesses in the world’s second largest pharma market. Companies are pumping up their new drug pipelines, while forging solid sales…
As Japan heralds the new imperial era of Reiwa, Eisai CEO Haruo Naito sat with Jiho to look back on…
Japan’s generic market is hitting a plateau soon. Incentive measures rolled out by the government since 2002 have driven its…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
In 2011 the Japanese pharmaceutical industry was rocked when a whistleblower exposed the falsification of trial data for the drug Diovan, the blockbuster blood pressure drug manufactured by pharma giant Novartis. The ensuing investigation led to the arrest of one…